Technology Transfer
Technology Transfer
VIB’s Innovation & Business team (VIB2) enables the essential links between VIB scientists and industry to translate our research into novel therapeutics, diagnostics, and other tangible applications. VIB2 encompasses in-house expert teams for patent applications (Intellectual Property), spin-off trajectories (New Ventures), internal drug discovery (Discovery Sciences), or external co-development, R&D, or license deals with biotech and pharma companies (Business Development).
Research valorization at CCB
Patient impact
Development of therapeutic and diagnostic products to improve patient outcomes
Clinical relevance
Collaboration with industry partners to ensure research is clinically applicable
Translation to clinic
Patenting research findings to attract industry interest and facilitate clinical application
Financial support
Generating income through research collaborations and licensing to fund furhter innovation
Industrial Collaborations
Best-in-Class MSI test available on Idylla
Diether Lambrechts and his team identified a set of 7 unique microsatellite instability markers, with a 98.7% concordance with available MSI tests. The novel biomarkers were exclusively licensed to Biocartis from VIB in 2013, marking the start of a collaborative MSI program of VIB and Biocartis, with the aim to support the development of a fully automated MSI test on Biocartis’ IdyllaTM platform.
Potential of novel TEAD-targeted therapy for solid tumors
In 2021, VIB and the Centre for Drug Discovery and Design secured an exclusive worldwide license deal with US-based Springworks Therapeutics for small molecule inhibitors of the TEAD pathway developed by Georg Halder and CD3. TEAD inhibition holds great promise as cancer therapeutic, with potential to treat lung cancer associated with asbestos exposure.
Advancing novel immuno-oncology assets
Lever Bio has taken scientific discoveries from CCB group leader Max Mazzone closer to patients through the licensing of the antibody-based therapeutic LVB-003. LVB-003 has the ability to interfere with the process through which solid tumors make their environment more acidic in order to grow and survive.
Building a new class of immunotherapy
The group Gabriele Bergers studies how blood vessels and immune cells interact inside tumors. In their research, they have discovered a mechanism that could help bring effective immune responses into tumors largely invisible to the immune system.
That discovery has evolved into a bispecific antibody called MST-0312, which is being developed by UK-based biotech company Mestag Therapeutics.
Basis for a new potential drug for medulloblastoma
Medulloblastoma is a rare, life-threatening brain tumor that mainly affects children. Research carried out by Peter Carmeliet provided the basis for a new potential drug: TB-403, an antibody against PlGF. TB-403 inhibits the production of new blood vessels towards certain brain tumors and hereby suppresses the survival of cancer cells.
Spin-offs
Montis Biosciences
Based on science from group leaders Peter Carmeliet and Max Mazzone, Montis Biosciences aims to therapeutically exploit cellular interactions between perivascular macrophages and the tumor vasculature to drive and sustain immune reactions against solid tumors.
Flamingo Therapeutics
Founded in 2020 based on science from group leader Chris Marine, Flamingo Therapeutics pioneers RNA-targeted therapies for oncology against undruggable transcription factors and splice variants. Flamingo merged with Dynacure in 2023 and subsequently became a clinical-phase company based in Belgium, France and USA.
Oncorious
Oncurious was founded in 2015 as a joint venture between VIB and Oxurion focussed on an asset from Peter Carmeliet. In 2017, additional immune-oncology assets were contributed to the company by the labs of Gabriele Bergers and Max Mazzone.